Published in Br J Cancer on March 01, 1979
Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A (1981) 1.34
The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer (1986) 1.24
From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumor agents. Yale J Biol Med (1982) 1.06
Effects of high doses of a series of new luteinizing hormone-releasing hormone analogues in intact female rats. Br J Cancer (1979) 1.05
Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A (1983) 0.94
Inhibition of growth of the transplantable rat chondrosarcoma by analogs of hypothalamic hormones. Proc Natl Acad Sci U S A (1983) 0.87
LHRH analogues in breast cancer: clever, but do we need them? Br J Cancer (1991) 0.84
Rapid induction of mammary carcinoma in the rat and the influence of hormones on the tumors. J Exp Med (1959) 2.92
Effects of high doses of a series of new luteinizing hormone-releasing hormone analogues in intact female rats. Br J Cancer (1979) 1.05
Potent agonist and antagonist analogues of luliberin containing an azaglycine residue in position 10. Biochem Biophys Res Commun (1978) 1.01
Effects of a gonadotropin-releasing hormone (GnRH) analogue (A-43818) on 7, 12- dimethylbenz (a)anthracene-induced rat mammary tumors. Histological and endocrine studies. Eur J Cancer (1977) 1.00
The effect of synthetic anti-oestrogens on the growth and biochemistry of rat mammary tumours. Eur J Cancer (1975) 0.98
The nature of estrogen and prolactin effect on mammary tumorigenesis. Cancer Res (1973) 0.98
Synthesis and biological activity of highly active alpha-aza analogues of luliberin. J Med Chem (1978) 0.97
THE RESPONSE OF EXPERIMENTALLY INDUCED MAMMARY TUMOURS IN RATS TO HYPOPHYSECTOMY AND TO PITUITARY STALK SECTION. Br J Cancer (1963) 0.96
A dissociation between ovarian dependent growth and estrogen sensitivity in mammary carcinoma. Endocrinology (1971) 0.95
A prognostic index in primary breast cancer. Br J Cancer (1982) 7.35
Expression and amplification of cyclin genes in human breast cancer. Oncogene (1993) 3.79
Relationship of oestrogen-receptor status to survival in breast cancer. Lancet (1979) 2.55
Relationship between primary breast tumor receptor status and patient survival. Cancer (1980) 2.49
Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology (2002) 2.35
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer (2004) 1.97
Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer (1989) 1.97
Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res (1978) 1.95
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer (2004) 1.91
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst (1995) 1.91
Relationship between oestrogen-receptor content and histological grade in human primary breast tumours. Br J Cancer (1978) 1.90
Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res (1990) 1.85
Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer (2005) 1.75
Prognostic factors in breast cancer -- the formation of a prognostic index. Clin Oncol (1979) 1.74
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer (2004) 1.72
Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer (2001) 1.65
Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res (1999) 1.65
Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology (2001) 1.62
Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology (2005) 1.53
Structure-function analysis of a novel member of the LIV-1 subfamily of zinc transporters, ZIP14. FEBS Lett (2005) 1.50
Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. J Pathol (1999) 1.47
Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma. Lancet (1983) 1.47
The individualised birthweight ratio: a more logical outcome measure of pregnancy than birthweight alone. Br J Obstet Gynaecol (1993) 1.44
C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer (1996) 1.44
Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res (1994) 1.43
Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat (2005) 1.41
Zinc transporters and cancer: a potential role for ZIP7 as a hub for tyrosine kinase activation. Trends Mol Med (2009) 1.40
Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer (1995) 1.40
Oestrogen-receptor status and sites of metastasis in breast cancer. Br J Cancer (1981) 1.38
Steroid receptors in early breast cancer: value in prognosis. J Steroid Biochem (1981) 1.31
Immunocytochemical localization of estrogen receptor in human breast tissue. Cancer Res (1988) 1.31
Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630. Br J Cancer (1986) 1.30
c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene (1998) 1.30
Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet (1981) 1.29
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology (2003) 1.29
Measurement of oestradiol receptors by five institutions on common tissue samples. Br J Cancer (1978) 1.26
INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res (2000) 1.26
c-erbB-4 protein expression in human breast cancer. Br J Cancer (2000) 1.25
Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer (1994) 1.25
The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer (1986) 1.24
Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. Br J Cancer (1987) 1.23
The binding of tamoxifen to oestrogen receptor proteins under equilibrium and non-equilibrium conditions. Eur J Cancer (1979) 1.23
Zinc transporter LIV-1: a link between cellular development and cancer progression. Trends Endocrinol Metab (2004) 1.21
Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression. Endocr Relat Cancer (2006) 1.20
An immunohistochemical examination of the expression of E-cadherin, alpha- and beta/gamma-catenins, and alpha2- and beta1-integrins in invasive breast cancer. J Pathol (1999) 1.20
Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer (2005) 1.19
E-cadherin as a prognostic indicator in primary breast cancer. Br J Cancer (2001) 1.15
Shipping stress and social status effects on pig performance, plasma cortisol, natural killer cell activity, and leukocyte numbers. J Anim Sci (1993) 1.15
Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival. J Pathol (2009) 1.12
Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocr Relat Cancer (2005) 1.12
Survival patterns in hormone treated advanced breast cancer. Br J Surg (1986) 1.12
A randomised controlled trial of medroxyprogesterone acetate in mastalgia. Ann R Coll Surg Engl (1990) 1.11
Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. Br J Cancer (1992) 1.10
Invasive lobular carcinomas of the breast--the prognosis of histopathological subtypes. Br J Cancer (1989) 1.09
The early results from a randomised study of radiotherapy versus Nolvadex (tamoxifen) as initial treatment for stage III breast cancer. Eur J Surg Oncol (1988) 1.09
Ki67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival. Eur J Surg Oncol (1992) 1.09
Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol (1989) 1.08
An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. Eur J Surg Oncol (1991) 1.08
Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. J Clin Endocrinol Metab (1997) 1.07
TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence. Int J Cancer (2001) 1.07
The effect of social deprivation on birthweight, excluding physiological and pathological effects. Br J Obstet Gynaecol (1995) 1.06
Effects of high doses of a series of new luteinizing hormone-releasing hormone analogues in intact female rats. Br J Cancer (1979) 1.05
EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival. Oncogene (1998) 1.05
Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clin Cancer Res (1996) 1.04
Biological and clinical associations of c-jun activation in human breast cancer. Int J Cancer (2000) 1.03
Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. J Clin Pathol (2007) 1.02
Interaction of the antioestrogen ICI 164,384 with the oestrogen receptor. J Steroid Biochem (1988) 1.02
BRCA1 expression levels predict distant metastasis of sporadic breast cancers. Int J Cancer (1999) 1.01
Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy. Breast Cancer Res Treat (1992) 1.01
Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer. J Steroid Biochem (1985) 1.00
Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer. Eur Urol (1997) 1.00
Methodology of immunohistological detection of oestrogen receptor in human breast carcinoma in formalin-fixed, paraffin-embedded tissue: a comparison with frozen section methodology. Histopathology (1993) 1.00
Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Res Treat (2008) 0.99
Up-regulation of the protein tyrosine phosphatase SHP-1 in human breast cancer and correlation with GRB2 expression. Int J Cancer (2000) 0.98
The effect of synthetic anti-oestrogens on the growth and biochemistry of rat mammary tumours. Eur J Cancer (1975) 0.98
Estradiol induction of retinoic acid receptors in human breast cancer cells. Cancer Res (1993) 0.97
Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment. Endocr Relat Cancer (2005) 0.97
Use of reverse transcription-polymerase chain reaction methodology to detect estrogen-regulated gene expression in small breast cancer specimens. Clin Cancer Res (1997) 0.95
Silver-stained nucleolar organiser region counts are of no prognostic value in primary breast cancer. Eur J Surg Oncol (1992) 0.95
Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer. Eur J Cancer (1996) 0.94
Abbott monoclonal enzyme immunoassay measurement of estrogen receptors in human breast cancer: a European multicenter study. Cancer Res (1986) 0.94
Expression of androgen receptor and growth factors in premalignant lesions of the prostate. J Pathol (1998) 0.94
A possible divergent role for the oestrogen receptor alpha and beta subtypes in clinical breast cancer. Int J Cancer (2000) 0.93
Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells. Br J Cancer (2006) 0.93
Metabolism of C 19 -steroids by homogenates of normal rat and mouse adrenal tissue and of the Snell transplantable rat adrenocortical tumour 494. Biochem J (1972) 0.92
Evaluation of an enzyme immunoassay for estrogen receptors in human breast cancers. Cancer Res (1986) 0.92
Determination of tamoxifen and biologically active metabolites in human breast tumours and plasma. Eur J Cancer Clin Oncol (1981) 0.91
A multicentre study into the reliability of steroid receptor immunocytochemical assay quantification. British Quality Control Group. Eur J Cancer (1991) 0.90
Quality control for the immunohistochemical demonstration of oestrogen and progesterone receptors. J Clin Pathol (2000) 0.90
Preliminary endocrinological evaluation of a sustained-release formulation of the LH-releasing hormone agonist D-Ser(But)6Azgly10LHRH in premenopausal women with advanced breast cancer. J Endocrinol (1986) 0.90
A comparative study of the interaction of oestradiol and the steroidal pure antioestrogen, ICI 164,384, with the molybdate-stabilized oestrogen receptor. J Steroid Biochem (1990) 0.90
Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival. Br J Cancer (1990) 0.89
Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications. Endocr Relat Cancer (2006) 0.89
The development of pain in young pigs associated with castration and attempts to prevent castration-induced behavioral changes. J Anim Sci (1993) 0.89
Endocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal patients with advanced breast cancer. Eur J Cancer Clin Oncol (1989) 0.89
Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes. Breast Cancer Res Treat (1996) 0.89
The role of four oestrogen-responsive genes, pLIV1, pS2, pSYD3 and pSYD8, in predicting responsiveness to endocrine therapy in primary breast cancer. Eur J Cancer (1993) 0.89